Transcripta Bio and Mayo Clinic Launch ALS Research
The partnership uses transcriptomic mapping to identify new therapeutic targets for sporadic and familial ALS.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Should medical research prioritize AI-driven drug discovery for rare neurodegenerative diseases?
Transcripta Bio and the Mayo Clinic have entered a research collaboration to identify new therapeutic targets for ALS. Researchers will use patient-derived tissue samples to generate molecular profiles for both sporadic and familial cases of the disease.
Why it matters
The study aims to accelerate the development of targeted therapies for ALS by mapping molecular data from patients with specific genetic profiles. By identifying new intervention targets, researchers hope to improve clinical care for both sporadic and familial disease variants.
Transcripta Bio will utilize its proprietary transcriptomic drug-discovery platform to analyze tissue samples. This involves single-cell RNA sequencing to map patient disease signatures against existing drug-response data.
The players
Transcripta Bio
A Palo Alto-based company focused on transcriptomic drug discovery for conditions including ASD, FSHD, and Huntington's Disease.
Mayo Clinic
A medical research center managing clinical recruitment and tissue collection for various neurodegenerative research initiatives.
The details
The research process involves creating patient-derived disease profiles through single-cell RNA sequencing—a technique that measures gene expression levels in individual cells. These molecular signatures are then compared against existing drug-response datasets to nominate potential intervention targets. This approach is intended to provide a systematic method for identifying therapies tailored to the specific biological mechanisms active in patients with diverse genetic profiles.
Timeline
2026: Merck & Co and Mayo Clinic entered a separate research collaboration.
The Tech Race
This collaboration follows a separate 2026 research agreement between the Mayo Clinic and Merck & Co. The effort reflects a broader trend of clinical centers integrating transcriptomic platforms to refine therapeutic discovery for complex neurodegenerative conditions.
The Mayo Clinic is currently recruiting living ALS patients for the study, covering both sporadic and familial cases. Patients interested in participating should consult their healthcare provider at the Mayo Clinic for information regarding eligibility.
The takeaway
The success of this collaboration will be measured by the nomination of new intervention targets for ALS patients with specific genetic markers. Stakeholders should monitor future announcements regarding drug candidate discovery and the integration of these findings into clinical trial pipelines.
Further reading
For broader trends in molecular research and development, see the Biotech section.
Source note: This article includes information reported by Pharmaceutical Technology.
Live Poll
Should medical research prioritize AI-driven drug discovery for rare neurodegenerative diseases?
